Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Abstract Backgrounds Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conventional therapies such as surgical resection, thyroid hormone therapy...

Full description

Bibliographic Details
Main Authors: Dong Chen, Xi Su, Lizhang Zhu, Hao Jia, Bin Han, Haibo Chen, Qingzhuang Liang, Chenchen Hu, Hao Yang, Lisa Liu, Peng Li, Wei Wei, Yongsheng Zhao
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Journal of Translational Medicine
Subjects:
Papillary thyroid cancer
Organoid
BRAFV600E
Combination therapy
Treatment prediction
Online Access:https://doi.org/10.1186/s12967-022-03848-z

Internet

https://doi.org/10.1186/s12967-022-03848-z

Similar Items